Table 1 Univariable analysis of clinical–pathologic features with Prosigna® score categories in the test development cohort (n = 79).
Prosigna 0–40 (n = 43) | Prosigna 41–60 (n = 19) | Prosigna 61–100 (n = 17) | p valuea | |
|---|---|---|---|---|
Age (years) | ||||
Mean | 63 | 64 | 66 | 0.1537 |
Median | 63 | 65 | 66 | |
Tumor size (mm) | ||||
Mean | 17 | 27 | 26 | 0.0374b |
Median | 14 | 22 | 21 | |
Lymph node | ||||
Positive | 11 (26%) | 8 (42%) | 6 (35%) | 0.5301 |
Negative | 32 (74%) | 11 (58%) | 11 (65%) | |
Tumor type | ||||
Ductal | 32 (74%) | 19 (100%) | 14 (82%) | 0.7369 |
Others | 11 (26%) | 0 (0%) | 3 (18%) | |
Nottingham grade | ||||
Grade III | 2 (5%) | 3 (16%) | 4 (24%) | 0.0485b |
Grade I and II | 41 (95%) | 16 (84%) | 13 (76%) | |
ER H-score | ||||
Mean | 268 | 271 | 256 | 0.3225 |
Median | 290 | 290 | 260 | |
PR H-score | ||||
Mean | 166 | 152 | 136 | 0.3300 |
Median | 190 | 170 | 135 | |
Ki-67 index | ||||
Mean | 13 | 23 | 42 | <0.0001b |
Median | 10 | 20 | 35 | |
